Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents

Diabetes, Obesity and Metabolism

Volumn 15, Issue 8, 2013, Pages 760-766

  Philis Tsimikas, A ^a   Del Prato, S ^b   Satman, I ^c   Bhargava, A ^d   Dharmalingam, M ^e   Skjoth T V ^f   Rasmussen, S ^f   Garber, A J ^g  

^a Whittier Institute for Diabetes   (United States)

^b UNIVERSITY OF PISA   (Italy)

^c ISTANBUL UNIVERSITY   (Turkey)

^d Iowa Diabetes and Endocrinology Center   (United States)

^e Bangalore Endocrinology and Diabetes Research Center   (India)

^f NOVO NORDISK A S   (Denmark)

^g BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Efficacy; Insulin degludec; Safety; Sitagliptin; Type 2 diabetes

Indexed keywords

FLEXPEN; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN DEGLUDEC; METFORMIN; PIOGLITAZONE; SITAGLIPTIN; SULFONYLUREA; UNCLASSIFIED DRUG;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIABETIC PATIENT; DISEASE DURATION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; WEIGHT CHANGE;

EID: 84879797718     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12115     Document Type: Article

References (25)

1. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl J Med 1993; 329: 977-986.
3. Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. New Engl J Med 1993; 329: 304-309.
4. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
5. American Diabetes Association (ADA). Standards of medical care in diabetes. Diabetes Care 2009; 32(Suppl. 1): S13-S61.
6. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203.
7. Rodbard HW, Jellinger PS, Davidson JA et al. Statement by an American association of clinical endocrinologists/American college of endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009; 15: 540-559.
8. UK Prospective Diabetes Study (UKPDS) Group. UK Prospective Diabetes Study 16: overview of 6years' therapy of type II diabetes: a progressive disease. Diabetes 1995; 44: 1249-1258.
9. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012; 55: 1577-1596.
10. Qaseem A, Humphrey LL, Sweet DE, Starkey M, Shekelle P. Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2012; 156: 218-231.
11. Jonassen I, Havelund S, Hoeg-Jensen T, Steensgaard DB, Wahlund PO, Ribel U. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res 2012; 29: 2104-2114.
12. Garber AJ, King AB, Del PS et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012; 379: 1498-1507.
13. Heller S, Buse J, Fisher M et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012; 379: 1489-1497.
14. Atkin SL, Bain SC, Gough S et al. Insulin degludec does not compromise efficacy or safety when given in a flexible once-daily dosing regimen compared to insulin glargine once daily at the same time each day in type 2 diabetes. Diabetologia 2011; 54(Suppl. 1): S53.
15. Birkeland KI, Raz I, Gough S et al. Insulin degludec in a flexible daily dosing regimen provides similar glycaemic control without increasing rates of hypoglycaemia compared to dosing the same time daily in type 2 diabetes. Diabetologia 2011; 54(Suppl. 1): S423.
16. International Conference on Harmonisation. ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice E6 (R1), Step 4. 10-6-1996.
17. World Medical Association. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects-Last amended by the 59th WMA General Assembly, Seoul. 2008.
18. Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med 2012; 29: 682-689.
19. Brod M, Barriocanal L, Rana A, Peyrot M. GAPP2™: global survey finds in the last month one in four type 2 diabetes patients do not take basal insulin as prescribed and over a third suffer hypoglycaemia. Diabetes 2012; 61(Suppl. 1): LB7(abstract 27-LB).
20. Kunt T, Snoek FJ. Barriers to insulin initiation and intensification and how to overcome them. Int J Clin Pract Suppl 2009; 164: 6-10.
21. Zinman B, Fulcher G, Rao PV et al. Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. Lancet 2011; 377: 924-931.
22. Zinman B, Philis-Tsimikas A, Handelsman Y et al. The effect of insulin degludec on glycemic control and nocturnal hypoglycemia compared with insulin glargine: a 1-year randomized trial in insulin-naïve people with type 2 diabetes. Diabetes 2012; 61(Suppl. 1): A269.
23. Onishi Y, Park S, Yoo S, Clauson P, Tamer S, Iwamoto Y. Insulin degludec improves glycemic control in insulin-naïve patients with type 2 diabetes: results of a randomized Pan-Asian trial. Diabetes 2012; 61(Suppl. 1): A272.
24. Ahren B. Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin. Diabetes Metab Syndr Obes 2010; 3: 31-41.
25. Liu SC, Tu YK, Chien MN, Chien KL. Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis. Diabetes Obes Metab 2012; 14: 810-820.